Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab-Reference-Cited by-同舟云学术

Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab

Published:2019-06 Issue:6 Volume:37 Page:355.e21-355.e29
ISSN:1078-1439
Container-title:Urologic Oncology: Seminars and Original Investigations
language:en
Short-container-title:Urologic Oncology: Seminars and Original Investigations

Author:

Ishihara Hiroki^ORCID,Takagi Toshio^ORCID,Kondo Tsunenori^ORCID,Homma Chie,Tachibana Hidekazu,Fukuda Hironori,Yoshida Kazuhiko,Iizuka Junpei,Kobayashi Hirohito,Okumi Masayoshi,Ishida Hideki,Tanabe Kazunari

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference29 articles.

1. Nivolumab versus everolimus in advanced renal-cell carcinoma;Motzer;New Engl J Med,2015

2. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma;Motzer;New Engl J Med,2018

3. Evolving systemic treatment landscape for patients with advanced renal cell carcinoma;McKay;J Clin Oncol,2018

4. Updated European Association of Urology Guidelines recommendations for the treatment of first-line metastatic clear cell renal cancer;Powles;Eur Urol,2018

5. Management of adverse events following treatment with anti-programmed death-1 agents;Weber;Oncologist,2016

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis;Cancer Treatment Reviews;2024-09

2. Anti-PD-L1 antibody retains antitumour effects while mitigating immunotherapy-related colitis in bladder cancer-bearing mice after CT-mediated intratumoral delivery;International Immunopharmacology;2024-08

4. Survival Impact of Glucocorticoid Administration for Adverse Events During Immune Checkpoint Inhibitor Combination Therapy in Patients with Previously Untreated Advanced Renal Cell Carcinoma;Targeted Oncology;2024-05-31

5. The correlation between immune-related adverse events and efficacy of immune checkpoint inhibitors;Japanese Journal of Clinical Oncology;2024-05-20